Agios Pharma (AGIO) Reports Updated Data for Mitapivat from Extension Phase of DRIVE PK Study in Patients with Pyruvate Kinase Deficiency

Pre-Open Movers 12/09: (THOR) (XBIT) (ARQL) Higher (DPLO) (THO) (M) Lower (more...)

Pre-Open Movers

Synthorx, Inc. (NASDAQ: THOR) 169.3% HIGHER; Sanofi (NYSE: SNY) and Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Synthorx for $68 per share in cash, which represents an aggregate equity value of approximately $2.5 billion (on a fully diluted basis).

XBiotech Inc. (NASDAQ:... More

Agios Pharma (AGIO) Presents Translational Data to Further Characterize the Role of TIBSOVO Treatment in IDH1 Mutant AML

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented translational data describing deep and durable molecular responses to treatment of TIBSOVO® (ivosidenib) and azacitidine and mechanisms of resistance and relapse to single agent treatment with TIBSOVO® in acute myeloid leukemia (AML) with an IDH1 mutation. The data were presented as part of the scientific program at the 2019 American Society of Hematology (ASH) Annual Meeting.

For 10 years, we have pioneered the science behind the role of IDH mutations in AML,... More

Agios Pharma (AGIO) Confirms Proof-of-Concept for Mitapivat (AG-348) Based on Preliminary Phase 2 Results in Patients with Non-Transfusion-Dependent Thalassemia

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today announced that clinical proof-of-concept has been established based on a preliminary analysis of the Phase 2 trial of mitapivat (AG-348) in patients with non-transfusion-dependent thalassemia. Mitapivat is an investigational, first-in-class, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase-R (PKR) enzymes.

The Phase 2 study has enrolled 12 of the intended 17 patients (nine with -thalassemia and three with -thalassemia). As of the November 14, 2019 data cutoff date, eight patients, all with -thalassemia, were evaluable for the primary endpoint of a hemoglobin increase of 1.0 g/dL... More